Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions

Baohui Hong, Jiabing Zheng, Rong Chen, Caiyun Zheng, Bin Du, Ruping Ni and Jing Yang ()
Additional contact information
Baohui Hong: Fujian Medical University Union Hospital
Jiabing Zheng: Fujian Medical University Union Hospital
Rong Chen: The Second Hospital of Sanming
Caiyun Zheng: Fuqing City Hospital Affiliated to Fujian Medical University
Bin Du: Fujian Medical University Union Hospital
Ruping Ni: Fujian Medical University Union Hospital
Jing Yang: Fujian Medical University Union Hospital

Drug Safety, 2023, vol. 46, issue 12, No 4, 1313-1322

Abstract: Abstract Immune checkpoint inhibitors (ICIs) have shown efficacy in tumor therapy. However, the risk of pulmonary toxicity from ICI-based treatment regimens remains unknown. We searched multiple databases and clinical trial websites from January 2015 to December 2021 and summarized the pulmonary toxicity profile and risk ranking of ICI-based treatments in cancer patients. We included a Phase III randomized clinical trial (RCT) in which the treatment group received at least one ICI and experienced pulmonary adverse events (PAEs). Our study, which included 104 RCTs, found the highest incidence of grades 1–2 and 3–5 treatment-associated PAEs (Tr-PAEs) in programmed death 1 (PD-1)+ chemotherapy and PD-1+ cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), respectively. The first incidence rates of grades 1–2 and 3–5 immune-mediated PAEs (Im-PAEs) were PD1+CTLA-4+ chemotherapy and PD-L1 + CTLA4, respectively. Cytotoxic T lymphocyte-associated antigen 4 + chemotherapy regimen and PD-L1+ targeted therapy drug (TTD)+ chemotherapy regimen had the highest risk of developing grades 1–2 and 3–5 Tr-PAEs. Programmed death-L1+ CTLA-4 has a higher risk of grade 3–5 Tr-PAEs than PD-L1. The risk of grade 1–2 pulmonary toxicity was significantly different in the high-dose and low-dose groups of nivolumab and atezolizumab. Nivolumab and atezolizumab induced dose-dependent grade 1–2 pulmonary toxicity. Among single-agent regimens, PD-1 showed the greatest grade 1–2 pulmonary toxicity. Programmed death-L1+ TTD+ chemotherapy showed the greatest grade 3–5 pulmonary toxicity in combination therapy. PD-L1+ TTD+ chemotherapy was associated with a higher risk of grade 3–5 Tr-PAEs and a lower risk of Im-PAEs. We recommend a targeted approach to managing PAE.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-023-01357-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:46:y:2023:i:12:d:10.1007_s40264-023-01357-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-023-01357-6

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().